Update information September 2017: The guideline has been revised throughout to link to MHRA advice and NICE technology appraisals that have been completed since original publication. Minor updates since publication August 2019: Links to the MHRA safety advice on the risk of using retinoids in pregnancy have been updated to the June 2019 version.
G.2. Chapter 7: Topical therapies for chronic plaque psoriasis
G.4. Chapter 9: Systemic therapy (second-line, non-biologic)
G.5. Chapter 10: Methotrexate and risk of hepatotoxicity
G.6. Chapter 11: Methotrexate and monitoring for hepatotoxicity
G.7. Chapter 12: Sequencing of biological therapy
Publication Details
Copyright
Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.
The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.
The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.
Publisher
Royal College of Physicians (UK), London
NLM Citation
National Clinical Guideline Centre (UK). Psoriasis: Assessment and Management of Psoriasis. London: Royal College of Physicians (UK); 2012 Oct. (NICE Clinical Guidelines, No. 153.) Appendix G, Excluded studies list (cost effectiveness)